Guru Ownership Trend
Guru Analysis for Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 2 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $2.17 M.
Top institutional holders include Cliff Asness and Paul Tudor Jones.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $21.63 M net outflow during the quarter.
Recent activity highlights Cliff Asness who increased their stake by 17.1%. Conversely, Paul Tudor Jones reduced exposure by 17.4%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Spyre Therapeutics, Inc. (SYRE)
Major holders include Cliff Asness ($1.05 M), Paul Tudor Jones ($421,880). According to the latest reported data, 2 tracked investment managers collectively hold approximately 29,238 shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $21.63 M, with 1 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited SYRE. The total reported sell value was $21.79 M.
Yes, 0 managers opened new positions in SYRE, and 1 increased their existing holdings. The total reported buy value was $154,043.82.